Novartis Pharmaceuticals Corporation Files New Drug Application for Certican -everolimus- for the Prevention of Rejection Following Heart and Kidney Transplantation.
Business Wire › December 20, 2002
Linked as:
Extract
Novartis Pharmaceuticals Corporation Files New Drug Application for Certican -everolimus- for the Prevention of Rejection Following Heart and Kidney Transplantation.
Business Editors/Health/Medical Writers
EAST HANOVER, N.J.--(BUSINESS WIRE)--Dec. 20, 2002--(NYSE: NVS) Novartis Pharmaceuticals Corporation announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Certican(TM) (everolimus). Novartis seeks to have Certican approved for the prevention of rejection episodes following heart and kidney transplantation. The Certican NDA reports on the...See the full content of this document
Sponsored links
